All Comments by Hiroshi Mori

  1. The apolipoprotein E epsilon4 allele is not a significant risk factor for frontotemporal dementia.
  2. Sequential phosphorylation of Tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation.
  3. The beta-amyloid precursor protein of Alzheimer's disease enhances neuron viability and modulates neuronal polarity.
  4. Estrogen blocks neurotoxic effects of beta-amyloid (1-42) and induces neurite extension on B103 cells.
  5. Interaction of apolipoprotein E epsilon 4 with other genetic and non-genetic risk factors in late onset Alzheimer disease: problems facing the investigator.
  6. Levels of trkA and BDNF mRNA, but not NGF mRNA, fluctuate across the estrous cycle and increase in response to acute hormone replacement.
  7. Mechanism of action of antiinflammatory drugs.
  8. Oligomerization of endogenous and synthetic amyloid beta-protein at nanomolar levels in cell culture and stabilization of monomer by Congo red.
  9. Par-4 is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer disease.
  10. Congo red inhibits proteoglycan and serum amyloid P binding to amyloid beta fibrils.
  11. Estrogen replacement therapy and longitudinal decline in visual memory. A possible protective effect?
  12. Apolipoprotein E polymorphism in patients with Alzheimer's disease, vascular dementia and ischemic cerebrovascular disease.
  13. Perlecan binds to the beta-amyloid proteins (A beta) of Alzheimer's disease, accelerates A beta fibril formation, and maintains A beta fibril stability.
  14. Frontotemporal dementia and Parkinsonism linked to chromosome 17: a new group of tauopathies.
  15. Superoxide mediates the cell-death-enhancing action of presenilin-1 mutations.